Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, discusses the FELIX trial of obecabtagene autoleucel (obe-cel) in acute lymphoblastic leukemia (ALL) at the Society of Hematologic Oncology 2024 Annual Meeting in Houston, Texas.
“[Obe-cel] is given in split dose based on tumor burden and has a much better safety profile than other [chimeric antigen receptor (CAR) T-cell therapies],” Dr. Jabbour said. He explained that obe-cel is also very effective, with a 78% response rate and a 97% measurable residual disease negativity rate.
“I hope this can become the new standard of care and will replace allogeneic hematopoietic stem cell transplant,” Dr. Jabbour added. “The early data are really promising.”